# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Calamity Jane (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI008-SYN
- Date: 2026-03-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Ruth Ann Kessler, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review: naltrexone, liver stiffness, mood and benefits. **S**

## History of present illness

Ms. Canary returns four weeks after intake. She has had no alcohol. Her tooth was removed at the dental clinic the day after her sick visit, and she finished the amoxicillin; the pain and swelling are gone. She has missed about eight of the last 21 naltrexone tablets: a bottle was lost when she moved her things, and some days she forgot. Cravings are milder on the days she takes it. She has had no nausea or stomach pain. She sleeps five to six hours and her mood is better. Her Medicaid and SNAP have been approved. She has called the peer recovery specialist twice and went to one women's meeting. **S**

| Element | Detail |
|---|---|
| Alcohol | None for four weeks |
| Naltrexone | About eight of 21 doses missed; no side effects |
| Dental abscess | Tooth removed; healed |
| Mood | PHQ-9 9; GAD-7 7 |
| Benefits | Medicaid and SNAP approved |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy better; weight rising |
| Ears, nose, mouth, and throat | Negative | Jaw pain and swelling gone |
| Gastrointestinal | Negative | No nausea, abdominal pain or yellowing |
| Psychiatric | Positive | Some low days; cravings milder; no thoughts of suicide or self-harm |

4 systems reviewed. **S**

## Current medications

- Thiamine 100 mg oral tablet, one tablet daily **S**
- Folic acid 1 mg oral tablet, one tablet daily **S**
- Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 78 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 50.9 kg; BMI 18.7 kg/m². All vital signs are synthetic.

Hemoglobin: 12.6 g/dL; MCV: 100 fL; Platelets: 191 10*3/uL; AST: 48 U/L (high); ALT: 33 U/L; GGT: 132 U/L (high); Albumin: 3.6 g/dL; PEth: 24 ng/mL (high); Liver stiffness (transient elastography): 9.6 kPa (high); PHQ-9: 9; GAD-7: 7. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.1 g/dL at baseline, 12.6 g/dL at this visit **S**
- MCV: 103 fL (high) at baseline, 100 fL at this visit **S**
- Platelets: 162 10*3/uL at baseline, 191 10*3/uL at this visit **S**
- AST: 96 U/L (high) at baseline, 48 U/L (high) at this visit **S**
- ALT: 44 U/L (high) at baseline, 33 U/L at this visit **S**
- GGT: 240 U/L (high) at baseline, 132 U/L (high) at this visit **S**
- Albumin: 3.4 g/dL (low) at baseline, 3.6 g/dL at this visit **S**
- PEth: 820 ng/mL (high) at baseline, 24 ng/mL (high) at this visit **S**
- PHQ-9: 14 at baseline, 9 at this visit **S**
- GAD-7: 11 at baseline, 7 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 122/78, pulse 78; weight 50.9 kg, BMI 18.7 |
| Mouth | Extraction socket healing cleanly |
| Abdomen | Soft and non-tender; no ascites |
| Skin | No jaundice, spider angiomas or palmar erythema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Severe alcohol use disorder in early recovery** (F10.20). Four weeks without alcohol; PEth 24 ng/mL, down from 820, agrees with what she reports. Daily tablets are hard to keep while she moves between places, so she chose the monthly extended-release injection. Safety reviewed: no thoughts of suicide or self-harm; the rifle remains with her friend. **S**
   - Extended-release naltrexone 380 mg intramuscularly today and every four weeks; oral naltrexone stopped.
   - Continue peer contact and the women's meeting.
2. **Alcohol-associated steatotic liver disease** (K70.0). Liver stiffness 9.6 kPa by transient elastography: above the 8 kPa below which advanced fibrosis is unlikely, but recent alcohol-related inflammation can raise the reading. AST 48, ALT 33 and GGT 132 U/L are falling; albumin 3.6 g/dL and platelets 191 are normal, and there are no signs of cirrhosis. FIB-4 is now 1.92. **S**
   - Repeat elastography and liver tests after about three more months without alcohol.
   - Hepatitis A and B vaccines at the preventive visit.
   - Acetaminophen no more than 2 g a day.
3. **Depressive symptoms during heavy drinking** (F32.A). PHQ-9 9 from 14 and GAD-7 7 from 11 after four weeks without alcohol: improving, which favors alcohol-induced symptoms. No antidepressant for now. **S**
   - PHQ-9 at each visit; weekly peer support; counseling offered through her new Medicaid coverage.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Self-management | Drinking since the last visit (her own account, day by day), cravings and triggers | Every visit | Completed today | No alcohol for four weeks; cravings milder |
| Laboratory | PEth, explained as part of care and not as a test of honesty | At baseline and about every one to two months | Completed today | 24 ng/mL, from 820 |
| Laboratory | Thiamine, folate and electrolytes | Thiamine before glucose and through recovery; electrolytes rechecked within a week if low | Completed today | Thiamine and folic acid daily; hemoglobin 12.6 g/dL, MCV 100 fL |
| Medication safety | Medicine for alcohol use disorder: adherence, side effects, opioid exposure | Every visit | Completed today | About eight of 21 oral doses missed; no side effects; changed to the monthly injection today |
| Laboratory | Liver enzymes on naltrexone | Baseline, within the first months of treatment, then periodically | Completed today | AST 48, ALT 33, GGT 132 U/L on naltrexone, all falling |
| Imaging | Liver fibrosis: FIB-4, transient elastography, albumin, INR, platelets | Elastography when FIB-4 is above 2.67, repeated after months without alcohol | Completed today | Liver stiffness 9.6 kPa; albumin 3.6 g/dL; platelets 191; FIB-4 1.92 |
| Examination | Weight, meals and food access | Every visit | Completed today | Weight 50.9 kg, BMI 18.7; two meals a day on most days |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) after two to four weeks without alcohol | At baseline, after two to four weeks without alcohol, then at least monthly while symptoms persist | Completed today | PHQ-9 9, item 9 scored 0; GAD-7 7 |
| Survey | Suicide-risk review, safety plan, firearm storage and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; rifle stored; 988 card carried |
| Self-management | Peer recovery support and mutual-help meetings | Weekly peer contact; meetings of her choice | Completed today | Two calls with the peer specialist; one women's meeting |
| Self-management | Housing, food, income and health coverage | Every visit | Completed today | Medicaid and SNAP approved; on the housing program waiting list |
| Self-management | Chewing tobacco | Every visit | Completed today | Still chewing; not ready to stop |
| Medication safety | Naloxone | Reassess at every visit | Not indicated | No opioid use; she turned down pain pills offered to her |

## Goal progress

- Finish withdrawal safely at home without a seizure or delirium. Outcome by 2026-03-09: Five days of gabapentin with daily nurse checks; CIWA-Ar 9 at intake, 10 at most, 2 at one week; no seizure, hallucinations or confusion. **S**
- No drinking, her goal, with a medicine for alcohol use disorder. In progress; target 2026-06-22. **S**
- Liver tests back to normal and a clear answer on liver scarring. In progress; target 2026-06-22. **S**
- Regular meals and a healthier weight. In progress; target 2026-06-22. **S**
- A room of her own and health coverage. In progress; target 2026-06-22. **S**
- PHQ-9 below 10, and reassessment once she has stopped drinking. In progress; target 2026-05-11. **S**

## Medication changes

- Stopped: Naltrexone 50 mg oral tablet, one tablet daily **S**
- Started: Extended-release naltrexone 380 mg by deep intramuscular injection into the buttock every four weeks, given by the clinic nurse **S**

## Guideline basis

- The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder (2018), American Psychiatric Association (American Journal of Psychiatry 2018;175(1):86-90)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine 2020;14(3S Suppl 1):1-72)
- The Healthcare Professional's Core Resource on Alcohol (2026), National Institute on Alcohol Abuse and Alcoholism
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology 2020;71(1):306-333)
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Preventive visit in four weeks with the second naltrexone injection and vaccines. Ten-week review in six weeks. Weekly peer contact. **S**
- Next scheduled visit 2026-04-27: periodic adult preventive visit. **S**
